Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Vir Biotechnology Inc

Healthcare US VIR

9.15USD
0.38(4.33%)

Last update at 2026-06-04T20:00:00Z

Day Range

8.919.29
LowHigh

52 Week Range

7.6127.48
LowHigh

Fundamentals

  • Previous Close 8.77
  • Market Cap1459.91M
  • Volume1444385
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-578.40301M
  • Revenue TTM79.60M
  • Revenue Per Share TTM0.59
  • Gross Profit TTM 1032.03M
  • Diluted EPS TTM-4.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 754.28M 549.80M -298.61100M -174.52900M -116.36400M
Minority interest - - - - 0.00000M
Net income 515.84M 528.58M -298.66500M -174.68300M -115.88400M
Selling general administrative 161.76M 160.79M 70.94M 37.60M 29.13M
Selling and marketing expenses - - - - -
Gross profit 1434.15M 1021.20M 76.37M 0.71M 10.67M
Reconciled depreciation 6.78M 5.81M 5.44M 4.52M 2.76M
Ebit 833.07M 276.89M -298.71900M -182.49600M -118.69200M
Ebitda 944.21M 282.70M 514.33M -177.97900M -115.93600M
Depreciation and amortization 111.14M 5.81M 5.44M 4.52M 2.76M
Non operating income net other - 129.05M -1.63100M - 0.00000M
Operating income 833.07M 276.89M -296.98000M -177.97900M -118.69200M
Other operating expenses 747.40M 666.32M 373.35M 178.69M 119.56M
Interest expense 183.15M 272.91M 3.81M 7.97M 0.00000M
Tax provision 238.44M 21.22M 0.05M 0.15M -0.48000M
Interest income 28.09M 0.44M 2.84M 8.51M 2.54M
Net interest income 28.09M 0.44M 2.84M 8.51M 2.54M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 238.44M 21.22M -0.05400M 0.15M -0.48000M
Total revenue 1580.47M 1087.07M 76.37M 0.71M 0.87M
Total operating expenses 601.09M 600.45M 373.35M 178.69M 119.56M
Cost of revenue 146.32M 65.86M - 143.07M -9.80000M
Total other income expense net -78.78800M 272.91M 296.68M 3.45M -0.21200M
Discontinued operations - - - - 0.00000M
Net income from continuing ops 515.84M 528.58M -298.66500M -174.68300M -115.88400M
Net income applicable to common shares 515.84M 528.58M -298.66500M -174.68300M -115.88400M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1960.09M 2802.09M 1954.27M 918.76M 512.07M
Intangible assets 22.59M 32.76M 33.29M 33.82M 35.69M
Earning assets - - - - -
Other current assets 40.95M 104.36M 73.00M 27.51M 13.38M
Total liab 369.85M 724.12M 522.42M 201.91M 88.13M
Total stockholder equity 1590.24M 2077.96M 1431.85M 716.85M 423.94M
Deferred long term liab - - 22.25M 7.07M -
Other current liab 91.35M 484.95M 232.59M 83.65M 46.91M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -237.82400M 377.24M -138.60000M -667.18400M -368.51900M
Other liab - 89.26M 47.62M 36.29M 28.92M
Good will 16.94M 16.94M 16.94M 16.94M 16.94M
Other assets 0.00000M 21.23M 9.78M 77.69M 9.25M
Cash 254.84M 848.63M 347.81M 436.57M 109.33M
Cash and equivalents - - - - -
Total current liabilities 175.41M 511.03M 341.24M 99.06M 59.21M
Current deferred revenue 64.85M 15.52M 98.21M 6.45M 6.18M
Net debt -130.30400M -720.65700M -214.25400M -370.01900M -109.09800M
Short term debt 12.87M 4.14M 3.93M 3.89M 0.24M
Short long term debt - - - - -
Short long term debt total 124.54M 127.97M 133.56M 66.56M 0.24M
Other stockholder equity 1828.86M 1709.84M 1571.54M 1385.30M 280.98M
Property plant equipment - 188.17M 130.05M 17.95M 16.31M
Total current assets 1588.23M 2519.08M 1562.82M 772.37M 403.00M
Long term investments 105.28M 23.93M 201.39M 0.00000M 24.29M
Net tangible assets - 2028.27M 1381.62M 666.10M 371.31M
Short term investments 1280.83M 1553.41M 360.33M 300.29M 274.10M
Net receivables 11.60M 26.40M 773.08M 1.90M -
Long term debt - - - - -
Inventory - - 8.59M - -
Accounts payable 6.33M 6.42M 6.52M 5.08M 5.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.81500M -9.12200M -1.09900M -1.27800M -0.60100M
Additional paid in capital - - - - -
Common stock total equity - - 0.01M 0.01M 0.01M
Preferred stock total equity - - - - -
Retained earnings total equity - - -138.60000M -667.18400M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 12.38M 21.23M 9.78M 15.75M 15.85M
Deferred long term asset charges - - - - -
Non current assets total 371.86M 283.01M 391.45M 146.40M 109.08M
Capital lease obligations 124.54M 123.84M 133.56M 70.45M 0.24M
Long term debt total - - - - 0.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1193.46100M -118.99700M -3.49300M -256.15800M -60.44100M
Change to liabilities -32.50300M 91.87M 38.78M 4.49M 9.34M
Total cashflows from investing activities -1193.46100M -140.81400M -9.86200M -256.15800M -60.44100M
Net borrowings -0.26000M -0.25900M -0.25000M 1.11M 1.11M
Total cash from financing activities 34.76M 100.33M 529.47M 449.24M 24.98M
Change to operating activities -72.16800M -720.26400M 37.35M 3.71M 3.15M
Net income 515.84M 528.58M -298.66500M -174.68300M -115.88400M
Change in cash 504.55M -88.07200M 328.67M 63.45M -129.55900M
Begin period cash flow 363.42M 451.49M 122.82M 59.36M 188.92M
End period cash flow 867.97M 363.42M 451.49M 122.82M 59.36M
Total cash from operating activities 1663.25M -47.58900M -190.94100M -129.63200M -94.09600M
Issuance of capital stock 28.46M 85.21M 529.91M 443.75M 24.39M
Depreciation 6.78M 5.81M 5.44M 4.52M 2.76M
Other cashflows from investing activities - - 0.18M 0.18M 0.18M
Dividends paid - - - - 0.00000M
Change to inventory - 52.81M - - 0.00000M
Change to account receivables 770.04M -773.07900M -773.07900M -773.07900M -773.07900M
Sale purchase of stock 3.22M 15.38M 327.27M -0.00300M 14.84M
Other cashflows from financing activities 3.34M 15.38M -0.18900M 322.93M 24.98M
Change to netincome 475.27M 46.41M 45.20M 32.33M 6.54M
Capital expenditures 68.03M 21.82M 6.55M 8.94M 8.19M
Change receivables - -773.07900M - - 0.00000M
Cash flows other operating - -12.49500M 16.75M - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - -88.07200M 328.67M - 0.00000M
Change in working capital 665.37M -628.39400M 29.52M 8.20M 12.49M
Stock based compensation 102.08M 83.78M 27.60M 8.72M 5.05M
Other non cash items 388.37M -52.56000M 45.21M 8.95M 1.97M
Free cash flow 1595.22M -69.40600M -197.49000M -138.57200M -102.28800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
VIR
Vir Biotechnology Inc		 0.38 4.33% 9.15 - 4.36 14.05 0.76 1.12 0.28
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Vir Biotechnology Inc

1800 Owens Street, San Francisco, CA, United States, 94158

Key Executives

Name Title Year Born
Dr. George A. Scangos Ph.D. Pres, CEO & Director 1948
Mr. Howard Horn Exec. VP, CFO & Sec. 1978
Dr. Ann M. Hanly Ph.D. Exec. VP & Chief Technology Officer 1970
Dr. Phillip Pang M.D., Ph.D. Exec. VP, Chief Medical Officer & Interim Head of Research 1975
Dr. Klaus Frueh Ph.D. Co-Founder & Scientific Advisor 1960
Dr. Lawrence Corey M.D. Co-Founder & Scientific Advisor NA
Dr. Louis J. Picker M.D. Co-Founder & Scientific Advisor NA
Ms. Johanna Friedl-Naderer Exec. VP & COO 1968
Mr. Steven J. Rice Exec. VP & Chief Admin. Officer 1960
Ms. Heather Rowe Armstrong VP of Investor Relations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions